In vivo pharmacological profile of 9‐hydroxyrisperidone, the major metabolite of the novel antipsychotic risperidone

Drug Development Research

Volumn 33, Issue 4, 1994, Pages 399-412

  Megens, Anton A H P ^a   Awouters, Frans H L ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

antipsychotic; in vivo; metabolite; pharmacology; risperidone

Indexed keywords

AMPHETAMINE; APOMORPHINE; CLONIDINE; COMPOUND 48-80; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; HALOPERIDOL; MESCALINE; NEUROLEPTIC AGENT; NORADRENALIN; PALIPERIDONE; RISPERIDONE; RITANSERIN; SEROTONIN RECEPTOR; TRYPTAMINE; UNCLASSIFIED DRUG; XYLAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CYANOSIS; DOSE RESPONSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SEIZURE; SUBCUTANEOUS DRUG ADMINISTRATION; TREMOR;

EID: 0028625436     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.430330403     Document Type: Article

References (28)

1. Effects of ganglion blocking agents on nicotine extensor convulsions and lethality in mice
2. Clinical overview of risperidone
3. Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
4. Effects of putative α‐adrenoceptor antagonists and of other compounds on the loss of the righting reflex and on exophthalmia induced by xylazine in the rat
5. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V. From haloperidol and pipamperone to risperidone
6. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part II. Neuroleptic activity spectra for dogs
7. 2 antagonistic properties
8. Monte Carlo method for the estimation of statistical significance in pharmacological testing
9. Biochemical profile of risperidone, a new antipsychotic
10. 2‐blocking activity of drugs
11. Further validation of in vivo and in vitro pharmacological procedures for assessing the α2/α1 selectivity of test compounds: (1) α‐adrenoceptor antagonists
12. Behavioral activity of rats measured by a new method based on the piezo‐electric principle
13. Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: A comparison with haloperidol
14. Interaction of haloperidol and risperidone (R 64 766) with amphetamine‐induced motility changes in rats
15. Behavioral disinhibition and depression in amphetaminized rats: A comparison of risperidone, ocaperidone and haloperidol
16. Antipsychotic profile and side‐effect liability of haloperidol, risperidone and ocaperidone as predicted from their differential interaction with amphetamine in rats
17. Survey on the pharmacodynamics of the new antipsychotic risperidone
18. Differential antagonism to amphetamine‐induced oxygen consumption and agitation by psychoactive drugs
19. Difenoxin (R 15 403), the active metabolite of diphenoxylate (R 1132). Part 2. Difenoxin, a potent, orally active and safe antidiarrheal agent in rats
20. Suprofen, a potent antagonist of acetic acid‐induced writhing in rats
21. Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new “in vivo” approach: The ATN‐test in rats
22. Protection from compound 48/80‐induced lethality. A simple test for inhibitors of mast cell‐mediated shock
23. Prevention of physostigmine‐induced lethality in rats. A pharmacological analysis
24. 2 antagonists
25. β‐Adrenergic agonists, potent non‐specific inhibitors of circulatory shock in rats
26. The regional brain distribution of risperidone and its active metabolite 9‐hydroxy‐risperidone in the rat
27. Comparative pharmacology of sabeluzole and its enantiomers